cerebral and peripheral ischaemia, and promotes nerve repair following traumatic spinal injury. Recent work has revealed a role for reduced VEGF expression in the pathogenesis of amyotrophic lateral sclerosis, a rare neurodegenerative disease caused by selective loss of motor neurons. In many instances, the neuroprotective effects of VEGF appear to result from a combination of the indirect consequences of increased angiogenesis, and the direct stimulation of neuronal function. However, more work is required to determine the specifi c functional role of direct neuronal effects of VEGF.
Introduction
Since its initial discovery in 1983 [1] and subsequent cloning of the gene in 1989 [2, 3] , vascular endothelial growth factor (VEGF-A, VEGF or vascular permeability factor) has been established to be an essential regulator of angiogenesis in both vertebrate development and in a variety of common chronic human diseases [4] . Alternative splicing of the human VEGF-A gene gives rise to at least six different transcripts, encoding isoforms (excluding signal peptide) of 121 (mouse equivalent, VEGF-A 120 ), 145 , 165 (mouse VEGF-A 164 ), 183, 189 and 206 amino acid residues [5] . All transcripts contain exons 1- 5 , encoding the signal sequence and core VEGFR-binding or VEGF/PDGF homology domain, and exon 8, with diversity generated through the alternative splicing of exons 6 and 7. Exon 6 encodes a heparin-binding domain, while exons 7 and 8 encode a domain that mediates binding to neuropilin-1 (NP1) and heparin. Human VEGF-A 165 , the most abundant and biologically active form, and VEGF-A 121 are secreted as covalently linked homodimeric proteins, whereas the larger isoforms, VEGF-A 189 and VEGF-A 206 , though thought to be secreted, are not readily diffusible and may remain sequestered in the extracellular matrix. VEGF-A is also the prototypical member of a family of related growth factors, which includes placental growth factor (PLGF), VEGFs B, C, and D, and the viral VEGF-Es encoded by strains D1701, NZ2 and NZ7 of the parapoxvirus Orf [6] [7] [8] . All VEGF family members are able to regulate angiogenesis, and in addition, VEGFs C and D are implicated as biologically important mediators of lymphangiogenesis; however, in contrast to VEGF-A, the precise biological roles of other VEGFs are not yet fully understood.
The biological functions of VEGF-A are mediated via the protein tyrosine kinase receptors, VEGFR2 (KDR/ Flk-1) and VEGFR1 (Flt-1) [4, 9, 10] . Additionally, certain VEGF isoforms bind to neuropilins (NPs), non-tyrosine kinase transmembrane receptors ( fi g. 1 ). NP1 is a non-tyrosine kinase receptor for VEGF-A 165 , the heparinbinding PlGF-2 isoform, VEGF-B, and VEGF-E [11] [12] [13] [14] . NP1 was fi rst identifi ed as a receptor for semaphorin 3A (Sema 3A), a member of a family of polypeptides involved in axonal guidance and patterning [15, 16] , and is expressed in endothelial cells, several tumour cell types and in certain types of sensory neuron including dorsal root ganglion (DRG), olfactory and optic nerves, as well as some sympathetic neurons [11, 17] . VEGF-A 165 also binds NP2 and VEGF-A 145 binds specifi cally to NP2 [14] , which has a similar domain structure to NP1 with 44% amino acid identity, and exhibits a distinct expression pattern in the developing nervous system [16, 18] . Sema 3A binds and induces neuronal growth cone collapse specifi cally through NP1, while Sema 3C, 3D and 3F recognise both NPs, though with differing affi nities [18] [19] [20] [21] . NPs also play essential roles in angiogenesis. Overexpression of NP1 in mice results in increased capillary formation, vasodilatation and malformation of the heart [22] , whereas mice defi cient in NP1 exhibit defects in embryonic axonal patterning and an array of vascular abnormalities including defective development of large vessels and impaired neural and yolk sac vascularisation [23] . Inactivation of both NP1 and NP2 causes a more severe failure of embryonic vascularisation resulting in death at E8.5 [24] . Though NP1-defi cient mice are not phenocopies of the VEGF and VEGFR knock-out mice (see below), mice null for both NP1 and NP2 resemble knock-outs of either VEGF or VEGFR2 more closely. However, despite the strong evidence that NP1 is both essential for angiogenesis and is a major receptor for VEGF-A 165 , its roles in VEGF biological functions have not been fully elucidated.
Expression of VEGF and VEGFRs in the Nervous System
During mouse embryogenesis, VEGF-A can be detected from embryonic day 7 (E7) in the extra-embryonic and embryonic endoderm, and by E8.5 is present at high levels in the trophoblast surrounding the embryo, and in the embryonic myocardium, gut endoderm, embryonic mesenchyme and amniotic ectoderm. Later in development, VEGF-A mRNA expression occurs in the mesenchyme and neuroectoderm of the head, and subsequently in the neuroepithelium and ventricular and choroid plexus epithelium of the developing central nervous system (CNS) [25] [26] [27] . VEGFR2 is highly expressed in vascular sprouts as they invade the neuroectoderm from day E11.5, and VEGFR2 expression remains high for the remainder of embryonic development and up to post-natal day 4 when vessel sprouting and endothelial proliferation are still very active [26] . VEGFR1 is also found in the vascular networks adjacent to the neural tube [25, 27] . In the developing rat brain, VEGF-A expression is confi ned to cortical neurons during early development, but undergoes a switch to maturing glial cells in close proximity to vessels, while expression in neurons falls to basal levels. However, exposure to hypoxia results in persistent neuronal expression and enhanced glial expression [28] . In the adult, expression of VEGF and VEGFR markedly declines in most tissues, and becomes restricted to a few regions of the brain, including the choroid plexus, area postrema and cerebellar granule cells [26, 29, 30] , and in densely vascularised regions of the CNS such as the pars distalis cells of the pituitary and in retinal glial cells following an hypoxic insult [31, 32] . VEGF expression is induced by hypoxia in astroglial cells [33, 34] , and is up-regulated in astrocytes at the site of spinal cord injury in the rat [35] and following CNS injury [36] . VEGF is also induced in peripheral nerves and dorsal root ganglia in a streptozotocin-induced model of type 1 diabetes [37] . Administration of VEGF to the cortex caused the up-regulation of VEGFR1 in brain astrocytes but not endothelial cells [38] .
Neurotrophic Effects of VEGF in Cultured Cells
Expression of VEGF by peripheral and brain neuronal and glial cells in the CNS and peripheral nervous system is thought to be important for providing the essential cues directing vascularisation of the developing brain and nervous system, but it is increasingly recognised that VEGF has direct effects on neurons and glial cells (summarised in table 1 ). VEGF stimulates several neurogenic, protective and neurotrophic activities, including proliferation of astrocytes [39] , Schwann cells [40, 41] , microglia [42] and cortical neurons [43, 44] ; protection of hippocampal, cortical, dopaminergic and peripheral sensory neurons as well as several neuronal cell lines against cell death induced by hypoxia, serum withdrawal or excitotoxic stimuli [39, 40, [45] [46] [47] ; and axonal outgrowth, survival and inhibition of growth cone collapse in sensory DRG and retinal ganglion neurons, and sympathetic neurons of the superior cervical ganglion (SCG) [40, [48] [49] [50] . Intracerebroventricular administration of VEGF also stimulates the proliferation of neuronal cells in the subventricular and subgranular zones of the hippocampal dentate gyrus [44] .
VEGF-A acting via VEGFR2 also has growth-promoting, survival and chemotactic effects on progenitor cells derived from regions of the brain that display spontaneous neurogenesis, such as the hippocampus, olfactory bulb and subventricular zone. VEGFR2 is expressed in mouse retinal progenitor cells [51] , while VEGF-A, VEGFR2, NP1 and NP2 are expressed in neural stem cells (NSC), and VEGF-A increased survival of these cells under anoxic conditions [52] . VEGFR1 is also up-regulated in astrocytes after CNS injury [36] . VEGF-A also stimulated the expansion of VEGFR2-expressing rat NSC in culture, an effect that was blocked by inhibiting VEGFR2 kinase activity [53] , and promoted the chemotaxis of neural progenitor cells from the subventricular zone, an effect dependent upon an increase in VEGFR2 expression mediated by FGF-2 [54] . VEGF-A enhanced migration, proliferation and survival in the neuroectodermal progenitor cell line, Dev [55] .
VEGF Signalling in Neurons
Survival Signalling A major effect of VEGF in many neuronal cell types is protection against cell death induced by serum withdrawal, or exposure to hypoxia or excitotoxic stimuli. In several of these studies, the survival effects of VEGF are mediated by the anti-apoptotic pathway involving phosphatidylinositol 3 -kinase (PI3K)-dependent activation of the serine/threonine kinase, Akt or PKB. In HN33 cells, a line generated by fusion of mouse hippocampal neurons and neuroblastoma cells, VEGF promoted a survival effect mediated through VEGFR2 receptors, PI3K/ Akt, increased phosphorylation of I B-␣ and nuclear translocation of the transcription factor NF-B [45, 56] .
VEGF also promoted survival of the neuroblastoma cell line SH-SY5Y, via PI3K-dependent (wortmannin-inhibitable) tyrosine phosphorylation of the voltage-gated potassium channel, Kv1.2 [47] . VEGFR2 signalling via the PI3K/Akt and the MEK/ERK pathways also protected hippocampal neurons from glutamate-induced death [46] , and the protective effect of VEGF in cerebellar granular neurons was dependent on the PI3K/Akt pathway but independent of ERK activation [57] . However, there is also evidence that the survival effects of VEGF in primary neuronal cultures may involve other mechanisms and, in some cases, be independent of the PI3K/ Akt pathway. VEGF rescued embryonic cortical neurons from hypoxic cell death via suppression of caspase-3 activity [58] , while VEGF protected hippocampal neurons against death induced either by hypoxia or methyl-D -aspartate via a pathway independent of both PI3K and inhibition of caspase activation [59] . VEGF and hypoxia induced activation of extracellular signal-regulated protein kinase (ERK) and increased phosphorylation of p90RSK and STAT (signal transducers and activators of transcription) 3a in embryonic cortical neurons, but both these stimuli notably failed to increase Akt activity [60] . 
Neuroproliferative Signalling
The neuroproliferative effects of VEGF in embryonic cortical neurons are mediated via multiple signalling pathways, including MEK/ERK, PLC-␥ and PI3K, and up-regulation of E2F transcription factors, as well as increased expression of several key components in the G 1 /S transition of the cell cycle, such as cyclins A, D1 and E, CD25 and PCNA (proliferating cell nuclear antigen) [61] . In DRG and SCG neurons, axonal outgrowth was inhibited by the MEK/ERK pathway inhibitor, PD98059 [40] . Chemotaxis of neural progenitors from the brain subventricular zone was mediated by VEGFR2 and was also dependent on an increase in VEGFR2 expression that required the presence of FGF-2 [54] .
Role of VEGF Receptor Tyrosine Kinases
In most of these studies, the effects of VEGF are mediated by VEGFR2 receptors as indicated by expression of VEGFR2 [40, 44, 45, 48, 56] , lack of effect of ligands for other VEGF receptors [45] , and effects of VEGFR2 inhibitors or anti-sense oligonucleotides [44, 46, 48, 57, 60] . The signalling pathways thought to be mediated by VEGFR2 in neuronal cells are shown in fi gure 2 . However, the expression of VEGFR1, but not VEGFR2, in hippocampal neuronal membranes was found to correlate with the ability of VEGF to inhibit outward delayedrectifi er potassium currents ( I k) [62] , suggesting that some effects of VEGF in neurons may be VEGFR2-independent.
Role of Neuropilins
Though VEGF-A 165 binds NP1 and NP2 with high affi nity, and NPs have an established role in neuronal patterning and homing, the role of NPs in mediating neuronal functions of VEGFs is presently unclear. Since VEGF-A 165 and the chemorepulsive factor Sema 3A bind to 
Fig. 2.
Neuronal receptors for VEGF and downstream signalling mechanisms. The major receptors for VEGF detected in neuronal cells are NP1 and VEGFR2/KDR. VEGF-A 165 also competes with Sema 3A for binding to NP1. Left: Associations between NP1 and the transmembrane proteins, plexin A1/2 and L1, are required for Sema 3A-induced growth cone collapse. In turn, L1 binds directly to both actin and ankyrin, which associates with spectrin and the associated actin cytoskeleton. Recruitment of the small Rho-like GTPase, Rnd, by the plexin A1 intracellular domain is suffi cient to induce growth cone collapse and this is antagonised by Rho D. NP1 also associates with the PDZ domain protein, synectin/NIP-1/GPIC. VEGF competition with Sema 3A may regulate associations between NP1 and either plexin A1/2 and/or L1, but this remains to be determined. Plexins have a large extracellular domain containing short cysteine-rich motifs also found in scatter factor receptors encoded by the MET oncogene family (black boxes), and regions of homology with semaphorins (white box); the plexin intracellular domain contains two separate regions of homology highly conserved within plexins but sharing little homology with other proteins (box and oval). L1 structure comprises an extracellular domain containing 6 Ig-like domains (ovals) and 5 fi bronectin type III regions (oblongs), and a large endodomain. Right: It is unknown whether VEGF binding to NP1 is suffi cient to trigger intracellular signalling independently of Sema 3A. VEGF has been reported to stimulate activation of PI3K/Akt, PLC-␥ and MEK/ERK pathways via VEGFR2 in a variety of neuronal cells (see text for details). NP1, at least in part, through the same binding site located in the b1/b2 domains of the NP1 extracellular region [63, 64] , one mechanism for the neurotrophic actions of VEGF-A 165 is competitive inhibition of the chemorepellent effects of Sema 3A. Indeed, the balance between Sema 3A and VEGF-A 165 , ligands for NP1 with opposing functional effects, may play an important role in regulating axonal guidance and neuronal viability. VEGF-A 165 enhanced migration, proliferation and survival in the neuroectodermal progenitor cell line, Dev, through antagonism of chemorepulsive and anti-apoptotic effects of Sema 3A mediated via competition for binding to NP1 [55] . Interestingly, this study showed that the chemorepellent effects of Sema 3A also required VEGFR1, consistent with VEGFR1 acting as a 'decoy' or sink, thereby attenuating VEGF-A 165 activity [4] .
Since Sema 3A binding to NP1 also requires the CUB or a1/a2 domains, not all semaphorin-dependent functions of VEGF may be modulated to the same degree by VEGF competition [63] . VEGF also exhibited neuroprotective effects in motor neuron-like NSC34 cells, which were blocked by a combination of neutralising antibodies to VEGFR2 and NP1, indicating a requirement for both receptors [65] . A recent study suggests that NP1 is a key mediator of the anti-chemorepulsive effect of VEGF-A 165 and the NP1 ligand, PlGF-2, in DRG neuronal explants [49] . Interestingly, the specifi c KDR inhibitor, SU5614, did not affect the anti-chemorepellent effects of VEGF and PlGF-2, while a specifi c peptide antagonist of VEGF binding to NP1 prevented inhibition of growth cone collapse [49] . These fi ndings suggest that NP1 may have a specifi c role in mediating neurotrophic actions of VEGF family members in DRG neurons independent of VEGFR2 and VEGFR1.
It is unclear whether neurotrophic effects of VEGF in DRG can be explained solely in terms of inhibition of Sema 3A chemorepulsion, or whether VEGF is able to signal through NP1 in a VEGFR2-independent manner. The signal transduction mechanisms triggered by ligand binding to NP1 remain to be fully delineated, though the small size of the NP1 intracellular domain suggests that it is unable to transduce a functionally productive signal itself and is dependent for signal generation on association with other components ( fi g. 2 ). This possibility is underscored by the fact that several NP-binding semaphorins, for example Sema 3A and Sema 3C, can act either as axonal repellents or attractants in different neuronal cell types, suggesting that the type of biological response mediated by NPs is determined by additional signalling components. Most semaphorins bind to their respective plexin receptors directly, but several members of the class 3 semaphorins (Sema 3A, 3C, 3D and 3F) instead bind to NP1 and/or NP2, which forms a signalling complex with plexins A1 or 2, transmembrane proteins with large intracellular domains [66] . How signals are transduced by NP/plexin A complexes is currently unclear, but similarities between the cytoplasmic plexin region and Ras GTPase-activating proteins (GAPs) suggest that plexins may have GAP-like activity towards small GTPases [67] . Consistent with this possibility, recruitment of the small Rho-family GTPase Rnd1 by plexin A1 is able to trigger cytoskeletal collapse, whereas another GTPase, RhoD, prevents plexin A1 signalling via Rnd1 [68] . Interactions between NP1 and L1, a member of the immunoglobulin superfamily of cell adhesion molecules containing a large endodomain, are also required for Sema 3A-triggered growth cone collapse [69] . L1 may regulate cytoskeletal integrity through direct binding to both actin and ankyrin, a cytoskeleton-associated protein linked to the spectrin-actin network [70] . Another candidate for mediation of NP1-dependent signalling is a PSD-95/Dlg/ ZO-1 (PDZ) domain protein, NP1-interacting protein-1 (NIP-1, identical to synectin and RGS-GAIP-interacting protein (GIPC)), which binds to a canonical carboxyl-terminal PDZ domain-binding motif in NP1 [71] . It is possible, though so far unknown, that VEGF is able to trigger anti-chemorepellent signals by regulating signalling mediated via plexin A or L1, or via NP1 associations with synectin or other PDZ domain proteins ( fi g. 2 ).
The different biological roles of semaphorin and VEGF binding to NP1 have been investigated using knock-in mice expressing NP1 variants defi cient in binding to semaphorins but retaining the ability to bind VEGF. These mutants perturbed the normal formation of axonal projections in cranial and spinal nerves and exhibited a variety of other effects on neurogenesis, but had none of the vascular defects observed in conditional endothelial cell-specifi c NP1 knock-out mice [72] . Furthermore, mice expressing NP1 mutants defi cient in semaphorin binding had a milder phenotype than NP1-null mice, indicating that some functions of NP1 in the development of the nervous system are independent of semaphorins. While indicating that semaphorin binding to NP1 is not essential for the vascular functions of NP1, these fi ndings also point to a requirement of VEGF binding for some of the neural functions of NP1. It cannot be precluded, however, that NP1 has neural functions mediated via other, so far unidentifi ed, cell surface ligands. NP1 can also mediate cell adhesion via heterophilic cell-cell interactions that have yet to be defi ned. The b1/b2 domains of NP1 are required for cell adhesion, but the interactions appear to be independent of both class 3 semaphorins and VEGF [73] . NP1 also mediated adhesion of endothelial cells independently of VEGF [74] .
Biological Role of Neurotrophic Effects of VEGF
The nervous and vascular systems are both highly ramifi ed structures that are physically associated and exhibit several striking developmental and anatomical parallels. These similarities raise several questions: Are the branching networks of nerves and blood vessels established independently or co-ordinately? If there is interaction between nerves and vessels, does one or the other play the key determining role, and, if so, what are the essential signals and hierarchical relationships between them? Finally, can endothelial cytokines, such as VEGF, multitask as neurotrophic factors, and vice versa? Recent research has begun to reveal the extent to which neural and vascular development is mechanistically integrated via reciprocal molecular interactions [75, 76] . The mechanistic links between nervous and vascular systems are illustrated ( fi g. 3 ) by the dependence of axonal guidance in the developing sympathetic system on the ability of VSMC in blood vessels adjacent to sympathetic axonal projections to express artemin, a chemoattractive factor of the glial cell line-derived neurotrophic factor (GDNF) family [77] .
Role of VEGF in Embryonic Neurogenesis
Establishment of the relative contributions of VEGFdependent angiogenesis and direct neurotrophic actions of VEGF to neurogenesis and neural function is an inherently diffi cult problem to address, because angiogenesis is so critical for both development and tissue growth. Largely for this reason, it is unresolved whether VEGF has an important biological role as a direct regulator of neuronal function or development independent of its angiogenic effect. Evidence from mice defi cient in VEGF or VEGFRs did not provide clues to the possible neural functions of VEGF, because defi ciencies in either the ligand or its two major receptors, VEGFR1 and VEGFR2, caused early embryonic lethality arising from a failure of vasculogenesis [78] [79] [80] [81] . Mice expressing only VEGF-A 120 (VEGF 120/120 ) and lacking the larger VEGF-A 165 and VEGF-A 188 isoforms, die peri-natally or by post-natal day 14 and display defective myocardial and retinal angiogenesis and ischaemic cardiomyopathy [82] [83] [84] . In addition, VEGF 120/120 mutants also exhibit a range of defects in the patterning of facial branchiomotor neurons due to impaired migration of neuronal somata rather than defective axonal guidance and similar to neuronal pathfi nding defects found in NP1-defi cient mice [85] . Mice expressing only VEGF-A 164 were normal and healthy, consistent with the dominant role of this isoform in mediating biological effects of VEGF. The lack of a more severe neural phenotype in mice lacking this isoform may be due to partial compensation by other VEGF isoforms or VEGFrelated factors able to perform similar neurogenic functions.
VEGF and Adult Neurogenesis
Though the precise role of VEGF in embryonic neurogenesis is unclear, evidence from several vertebrate systems in which neurogenesis occurs in the adult state, indicates that endothelial cells play an essential role by generating a microenvironment, or vascular niche, that promotes the proliferation of NSC. In the hippocampal subgranule zone, a region where neurogenesis occurs throughout adult life, dividing neural progenitors are concentrated in dense clusters around blood vessels, and neurogenesis is tightly co-ordinated with angiogenesis [86] . During neurogenesis in the higher vocal centres of adult songbirds, testosterone induces neurogenesis and endothelial cell proliferation via up-regulation of VEGF and VEGFR2, which stimulate an angiogenic response, leading to increased production of the brain-derived neurotrophic factor (BDNF) by the newly formed vasculature ( fi g. 3 ); BDNF, in turn, is able to support subsequent neuronal differentiation [87] .
Effects of VEGF in NSC
As mentioned above, VEGF acting via VEGFR2 promotes the migration, survival and proliferation of neural progenitors [53] [54] [55] . However, it is unclear whether VEGF acting directly on NSC, or an indirect effect of VEGF-induced endothelial cell proliferation, plays the more essential role. NSC are preferentially localised in areas contiguous to blood vessels [86] [87] [88] and communication between these cell types appears to be essential for maintaining the capacity of NSC for self-renewal, whereas prevention of the interaction is a stimulus for neuronal differentiation [89] . In this study, self-renewal of NSC was dependent both on FGF-2 stimulation of NSC proliferation, and on the production of soluble factors by endothelial cells and activation of Notch1 signalling in NSC.
VEGF is strongly expressed by neural progenitor cells in the ventricular zone of the developing brain, and is a key signal orchestrating vascularisation of the neuroectoderm [76] . The importance of VEGF in brain development is demonstrated by the fi nding that conditional homozygous inactivation of VEGF in the neural tube of the developing mouse brain using cre/lox technology caused a severe impairment of brain vascularisation and resulted in massive neuronal apoptosis [90] . This study indicates that VEGF is essential for brain angiogenesis and, either directly or indirectly, for the production of signals necessary for neuronal survival. Together with the other work considered in this section, these fi ndings are consistent with a key role for VEGF, acting in concert with endothelial-derived neurotrophic cytokines, in a signalling network that coordinates angiogenesis and neurogenesis, but it is again unclear whether direct effects of VEGF on neuronal cells are important for mediating its biological role in the brain.
Role of VEGF in Peripheral Nerve Pathfi nding
Contrasting conclusions about the biological role of direct neuronal effects of VEGF have recently come from studies of peripheral nerve development. An earlier investigation found that local ablation of the peripheral nervous system by UV irradiation, did not disrupt the patterning of large vessels in embryonic chick limbs [91] . A re-examination of this question in mouse limb skin showed that peripheral nerves associate preferentially with arteries expressing the arterial marker, ephrin B2, prior to investment of arteries with VSMC. Furthermore, mutations in neurogenins 1 and 2 that cause a loss of peripheral sensory nerves and their associated Schwann cells, impaired the normal branching pattern of blood vessels, resulting in a depletion of intermediate-size branches and reduced expression of markers of arterial differentiation [92] . A requirement of nerve-derived VEGF production for arterial differentiation has been demonstrated by neuron-specifi c Cre recombinase-mediated knock-out of VEGF in the mouse [93] . Consonant with these fi ndings, either VEGF-A administration, or inhibition of VEGF-A signalling using soluble VEGFR1, perturbed vascularisation of developing forelimbs in quail embryos, but had little effect on the pattern of innervation [94] . Furthermore, inhibition of either VEGFR2 or VEGF sequestration using soluble VEGFR1 had no effect on axonal outgrowth in embryonic DRG explants while severely disrupting the local capillary network [95] . These studies indicate that while peripheral nerves form a template determining the pattern of vascularisation during vertebrate limb development, VEGF production by glial cells and sensory neurons acts as a key mediator of vascular patterning and arterial differentiation but is not essential for axonal pathfi nding.
Role of VEGF in Invertebrate Neurogenesis
The discovery of invertebrate VEGF/VEGFR systems promises to yield fresh insights into the biological functions performed by neuronal effects of VEGFs. Four VEGFR-like molecules, VERs (vascular endothelial growth factor receptor related) 1, 2, 3 and 4, have been identifi ed in the nematode worm, Caenorhabditis elegans , which lacks both a vascular circulatory system and blood cells. C. elegans VERs are localized to cells of neural origin, suggesting a role in neurogenesis [96] . Defi nitive identifi cation of a VER ligand is awaited, although a putative homologue of the Drosophila PDGF/VEGF-like factor, PVF1, was revealed by a survey of the C. elegans genome [96] . In Drosophila , the VEGF/PDGF-like factors, PVFs 1-3, and their receptor, PVR, play key roles in the migration of border cells during oogenesis and hemocytes (blood cells) in development [97] [98] [99] . Disruption of PVR function in Drosophila causes defects in both CNS axon tract morphology and positioning of glial cells, though this appears to be mediated indirectly by a failure of macrophages to migrate to the CNS and engulf apoptotic neural cell corpses rather than through the loss of a direct neurogenic role of the PVF/PVR axis [100] . VEGF and VEGFR genes are expressed in tubular structures of the gastrovascular system of the jellyfi sh, Podocoryne carnea [101] , a member of Cnidaria, the simplest invertebrate phylum of the animal kingdom possessing tissue organization and a complex neural network. P. carnea VEGF/VEGFRs are also present in the endoderm when undifferentiated cells migrate and differentiate into plate cells, suggestive of a role in cell migration or homing. These fi ndings suggest that VEGF and VEGFR-like molecules may have been co-opted to perform roles in neural development of some invertebrate species, but they also indicate that they may have had more general roles in cell migration and the formation of tubular structures in diverse developmental contexts, evolutionarily antecedent to the emergence of a vascular system.
Therapeutic Potential of VEGF for Neural Disease
Cerebral and Peripheral Nerve Ischaemia VEGF is strongly implicated in mediating the vascular response to cerebral ischaemia resulting from stroke. Expression of VEGF, its receptors, VEGFR1 and VEGFR2, and the key hypoxia-inducible transcription factor, HIF-1 ␣ , is induced by focal ischaemia in the rat brain [102] [103] [104] [105] [106] ; furthermore, hypoxia-inducible expression of VEGF, VEGFR1 and VEGFR2 precedes neovascularisation following cerebral ischaemia [107] . The ability of VEGF both to stimulate angiogenesis and to elicit direct neurotrophic effects makes it an attractive candidate for repair or regeneration of nerves damaged by ischaemic disease. In support of such a protective role, inhibition of VEGF increased brain infarct size in ischaemia [103] and also delayed brain repair following injury [108] . However, VEGF up-regulation following cerebral ischaemia may have deleterious effects due to its permeability-increasing activity. VEGF production by tumourigenic glioblastoma cells causes intracerebral haemorrhage resulting from the formation of unstable vessels [109] , while VEGF antagonism has been shown to reduce brain oedema, tissue damage and blood-brain barrier leakage after ischaemia/reperfusion injury in animal models [110, 111] . Both the timing of VEGF treatment and the route of delivery seem to be important determinants of its therapeutic effect in cerebral ischaemia. While late (48 h post-ischaemia) intravenous administration of VEGF enhanced angiogenesis and signifi cantly improved neurological recovery, early treatment with VEGF (1 h postischaemia) increased brain-blood barrier leakage, haemorrhagic transformation and ischaemic lesions [111] . Administration of VEGF either by topical application to the brain surface, or by intracerebroventricular infusion reduced brain oedema and infarct volume [112, 113] , though this was dependent on the concentration used [114] . The neuroprotective effect of intracerebroventricular infusion was associated with increased angiogenesis, and both acute and longer term enhancement of neuronal survival [115] . There may also be a role for other VEGF family members in protection against ischaemic brain damage. Augmented cerebral ischaemic injury was reported in VEGF-B-defi cient mice [116] , and PlGF expression was up-regulated following cerebral ischaemia in mice, while NP1 was also highly expressed in vessels and neurons [117] .
VEGF may also have therapeutic potential for the treatment of peripheral nerve disease. Peripheral neuropathy is a common complication of diabetes and critical limb ischaemia, resulting in part from hypoxic damage to the vasa nervorum and consequent sensory defi cits in the lower extremities. VEGF gene transfer restored peripheral nerve function in streptozotocin-induced diabetic neuropathy [118] and hindlimb ischaemia [119] .
Though it is attractive to postulate a direct neuroregenerative role of VEGF, it is diffi cult in many of these examples to assess whether neural repair or neuroprotection are the results of a direct neurotrophic effect, or are secondary to VEGF-driven angiogenesis and hence improved perfusion of the ischaemic territory. However, a recent study suggests that in mice transgenically overexpressing VEGF specifi cally in the brain, protection against cerebral ischaemia may not signifi cantly benefi t from the effects of VEGF-driven angiogenesis but instead is largely due to a direct neuroprotective effect resulting from inhibition of apoptotic pathways such as caspase-3 activation [120] . Though mice overexpressing VEGF had a constitutively greater cerebral vessel density that was associated with enhanced overall cerebral blood fl ow, blood fl ow to the ischaemic territory was actually reduced [120] .
Nerve Repair VEGF has also been investigated for its ability to promote nerve repair following spinal injury. Expression of VEGF and its receptors are increased in lesions caused by traumatic injury to the spinal cord [121, 122] . VEGF stimulated axonal regeneration in preparations of sciatic nerves in vitro [123] , and adenoviral VEGF administration promoted regeneration of corticospinal tract axons in rats following transection of the spinal cord [124] . Following traumatic spinal injury, treatment with recombinant VEGF 165 also caused an improvement in recovery, associated with increased vessel density and reduced apoptosis in the lesion area, and increased expression of VEGFR1, VEGFR2, NP1 and NP2 [125] . However, VEGF-A 165 therapy was also found to have a worsening effect on the lesions caused by spinal cord injury possibly secondary to its effect on vascular permeability [126] .
Neurodegenerative Disease
Perhaps the strongest evidence that a direct neuronal effect of VEGF is biologically important for normal function of adult nerves has come from studies of the rare neurodegenerative disease, amyotrophic lateral sclerosis (ALS), also called Charcot or Lou Gehrig's disease. ALS is a progressive neurodegenerative disorder resulting from the selective death of motor neurons, and usually fatal within 1-5 years of onset [127, 128] . The disease affects 1-2 per 100,000 people, 1 90% of cases having no known cause or genetic linkage, and referred to as sporadic ALS. Approximately 5-10% of cases are familial, and of these, 20% are thought to be caused by mutations in the enzyme superoxide dismutase-1 (SOD1). Transgenic expression of SOD1 mutants causes an ALS-like disease in mice, and is associated with a dramatic increase in SOD1 activity, suggesting that the pathogenesis involves a toxic effect of gain-of-function SOD1 mutants [128] . The fi rst indication of a role for VEGF in ALS was the discovery that homozygous deletion of the hypoxiaresponse element in the VEGF promoter in mice (HRE -/-) resulted after 5 months in the development of motor neuron degeneration and other neuropathological features characteristic of mouse models of ALS and ALS patients, such as specifi c depletion of choline-acetyltransferase-positive neurons, occurrence of neurofi lament inclusions and selective loss of large myelinated motor neurons [65] . HRE deletion caused a subtle tissue-specifi c loss of hypoxia-inducible VEGF expression in neural tissue, accounting for the lack of a more severe phenotype in these mice that would result from a more general loss of VEGF expression [65] . The adult-onset ALS-like disease observed in HRE -/-mice was, at least in part, secondary to impaired neural vascular perfusion, though this was not caused by any apparent defect in vascularisation. Hypoxic induction of VEGF was also impaired in mice expressing SOD1 mutants [129] . The relevance of VEGF for human ALS is suggested by the fi nding that individuals homozygous for certain polymorphisms in the VEGF promoter have a signifi cantly increased risk of ALS (1.8 times greater), associated with decreased circulating levels of VEGF and reduced VEGF gene expression [130] . Though mice expressing SOD1 mutants develop ALSlike symptoms and die more rapidly than HRE -/-mice, 'knock-in' of the HRE deletion in SOD1 G93A mice reduced survival still further [130] . Consistent with a direct motor neuron effect of VEGF in ameliorating ALS-like symptoms, neuronal overexpression of VEGFR2 delayed onset of disease in SOD1 G93A mice [131] , while VEGF protected cultured motor neuron-like NSC34 cells against cell death [65] . The fi ndings that intracerebroventricular VEGF protein administration delayed onset and improved survival in a SOD1 G93A rat model, while VEGF gene delivery using a lentiviral vector delayed the onset and progression of ALS-like disease in SOD1 G93A transgenic mice [131, 132] , suggest that VEGF therapy might have potential for the treatment of this currently incurable disease.
Further evidence supporting a role of endogenous VEGF in protecting motor neurons against degenerative disease has come from a mouse model of X-linked spinobulbar muscular atrophy (SBMA or Kennedy's disease), a rare inherited neuromuscular disease characterised by degeneration of lower motor neurons, and caused by a polyglutamine repeat expansion in the androgen receptor (AR). Transgenic overexpression of an AR gene carrying the polyglutamine-encoding repeat (CAG) recapitulated key features of human SBMA, and resulted in impaired VEGF expression, while VEGF rescued motor neuronlike cells (a hybrid of motor neurons and neuroblastoma cells) from death induced by AR polyglutamine constructs [133] .
While much less is known regarding the role of VEGF in common chronic neurodegenerative diseases, vascular pathologies are recognised to play an important role in the most common forms of dementia. There is strong evidence that in a substantial proportion of cases, the pathogenesis of Alzheimer's disease (AD) involves an angiopathy characterised by irregularities in arterial wall structure and an increased capillary density associated with ␤ -amyloid peptide deposits [134, 135] . Vascular dementia (VD), the second most common form of age-related dementia, is thought to result from multiple brain infarcts leading to loss of brain tissue [136, 137] . A high proportion of AD patients also show evidence of cerebrovascular disease [137] . These fi ndings implicate VEGF as a potential mediator of pathological neovascularisation induced either by ␤ -amyloid peptide signalling or in response to cerebral ischaemia. Increased VEGF immunoreactivity is observed in the neocortical astrocytes and large intraparenchymal vessels of AD patients [138] , and VEGF and FGF-2 are also present in the choroid plexus in AD [139] . Intrathecal levels of VEGF were also elevated in AD and VD patients and these were related to the severity of the disease [140] . Genome-wide expression profi ling of AD brain mRNA reveals a generalised depression of gene expression accompanied by up-regulation of a specifi c subset of genes encoding for pro-apoptotic, proinfl ammatory and pro-angiogenic proteins, including the cell death receptor, FAS, interleukin-1 ␤ , COX-2 and VEGF [141, 142] . Accumulation of VEGF also colocalised with ␤ -amyloid deposits in the brains of AD patients [143] .
There is some evidence suggesting that VEGF could have a protective role against the selective degeneration of dopaminergic neurons in Parkinson's disease. Thus, VEGF had a neuroprotective effect against the death of dopaminergic neurons induced by 6-hydroxydopamine both in culture and in a mouse model [144] .
Conclusions and Perspectives
There is growing evidence that the mechanisms controlling development of the neural and cardiovascular systems intermesh to a remarkable degree. Members of the neuropilin, semaphorin and plexin families, originally thought to be primarily regulators of axonal guidance, are also critically important for several aspects of cardiovascular development. In addition to the vascular defects found in NP knock-out mice, targeted disruption of Sema 3C results in impaired development of the aorta [145] , while Sema 6D signalling via plexin A1 plays a key role in cardiac morphogenesis [146] , and genetic ablation of Sema 3E and its receptor plexin D1 disrupts embryonic intersomitic vascular patterning [21] . Conversely, VEGF-A, once identifi ed as a specifi c endothelial cytokine, is now well established to exert direct neuroprotective, neurotrophic and neuroproliferative effects in a variety of neural cell types in culture, and promote both neurogenesis and neuroprotection in animal models of cerebral ischaemia, neurodegenerative diseases and traumatic nerve injury. Tyrosine kinase receptors for VEGF are expressed in neural tissue, and specifi c isoforms of VEGF-A and other VEGF family members bind with high affi nity to NP1 and/or NP2. Though many details of the mechanisms underlying direct neuronal effects of VEGF remain to be determined, VEGF induces a variety of early signalling events in neurons, and at least some neuronal effects of VEGF are mediated by VEGFR2 and/or NP1. New modalities of VEGF signalling relevant for neuronal and vascular systems are also continuing to emerge, as illustrated by mediation of the role of Sema 6D in cardiac morphogenesis via complexes of plexin A1 and VEGFR2 [146] .
Despite the abundant and compelling evidence that VEGF can promote both direct and indirect effects on neuronal cells, there has remained a considerable degree of uncertainty regarding the physiological importance of these effects either during development or in the adult. While endothelial cells and angiogenesis play key roles in neural development, and may be particularly important in providing signals necessary for the self-renewal of NSC, the precise roles of angiogenesis and direct neurotrophic effects of VEGF either during embryonic or adult neurogenesis, or in protective responses to ischaemia and adult nerve injury, remain unclear. However, evidence from recent studies of mice specifi cally lacking the most abundant and biologically active VEGF isoform, VEGF-A 165 , indicate that it plays an important role in the migration and pathfi nding of some embryonic nerves. VEGF has also shown promise in animal studies as a potential future therapy for nerve damage caused by spinal cord injury, cerebral ischaemia and in the rare neurodegenerative disease, ALS. Though the potent vascular permeability-increasing effect of VEGF is a potential obstacle to harnessing its therapeutic potential in nerve disorders, the experience of VEGF clinical trials for cardiovascular disease suggests that, in humans at least, VEGF therapy is safe and well tolerated. If results in animal studies can be replicated in humans, VEGF may emerge as an alternative treatment for neurodegenerative disease in the future.
